DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering Cancer Center
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
DermTech (DMTK) Reports Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering Cancer Center
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
™ Campaign to Join the Pledge to Stop Melanoma Deaths
In honor of Melanoma and Skin Cancer Awareness Month, DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by the non-invasive DermTech Smart Sticker
™ platform and its melanoma test, the Pigmented Lesion Assay or PLA, is launching the #Stickit2Melanoma campaign, urging the public to get proactive about skin exams. One in five Americans develop skin cancer by the age of 70, and every hour of every day one American dies from melanoma. It is not only one of the most common cancers diagnosed in the U.S., but also the deadliest of skin cancers. Yet, when diagnosed at a localized stage, the 5-year relative survival rate for melanoma is 99%. Early detection saves lives, and just one annual screening can uncover issues beneath the skin’s surface at the most treatable stage.